East China Pharmaceutical: Clinical trial application for the injectable DR10624 of its holding subsidiary has been approved.

East China Pharmaceuticals announced that its holding subsidiary, Zhejiang Daor Bio-Technology Co., Ltd., has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The clinical trial application for DR10624 injection has been approved, with indications for hypertriglyceridemia. DR10624 is a long-acting triple-specific agonist targeting fibroblast growth factor 21 receptor, glucagon receptor, and glucagon-like peptide-1 receptor, which is globally the first innovative drug developed by Daor Bio.